Savill Corrine has filed 21 insider transactions across 1 company since February 2023.
Most recent transaction: a grant/award of 175000 shares of Cullinan Therapeutics, Inc. ($CGEM) on February 18, 2026.
Activity breakdown: 0 open-market purchases and 5 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 18, 2026 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | A | Stock Option (Right to Buy) | 175000 | $0.00 | 175,000.0000 | 59,076,259 | 9999.99% | 0.30% |
| Feb. 19, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 58,510,610 | 9999.99% | 0.13% |
| Feb. 19, 2025 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | A | Common Stock | 37500 | $0.00 | 240,990.0000 | 58,510,610 | 18.43% | 0.06% |
| Feb. 22, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | A | Stock Option (Right to Buy) | 75000 | $0.00 | 75,000.0000 | 42,900,083 | 9999.99% | 0.17% |
| Feb. 22, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | A | Common Stock | 37500 | $0.00 | 203,490.0000 | 42,900,083 | 22.59% | 0.09% |
| Feb. 1, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | S | Common Stock | 40000 | $16.18 | 165,990.0000 | 42,900,083 | 19.42% | 0.09% |
| Feb. 1, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | M | Stock Option (Right to Buy) | 40000 | $0.00 | 70,331.0000 | 42,900,083 | 36.25% | 0.09% |
| Feb. 1, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | M | Common Stock | 40000 | $4.30 | 205,990.0000 | 42,900,083 | 24.10% | 0.09% |
| Jan. 29, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | S | Common Stock | 40000 | $14.09 | 165,990.0000 | 42,900,083 | 19.42% | 0.09% |
| Jan. 29, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | M | Stock Option (Right to Buy) | 13997 | $0.00 | 0.0000 | 42,900,083 | 100.00% | 0.03% |
| Jan. 29, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | M | Stock Option (Right to Buy) | 26003 | $0.00 | 110,331.0000 | 42,900,083 | 19.07% | 0.06% |
| Jan. 29, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | M | Common Stock | 40000 | $4.30 | 205,990.0000 | 42,900,083 | 24.10% | 0.09% |
| Jan. 22, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | M | Common Stock | 14559 | $4.30 | 184,674.0000 | 42,900,083 | 8.56% | 0.03% |
| Jan. 22, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | S | Common Stock | 4125 | $12.02 | 165,990.0000 | 42,900,083 | 2.42% | 0.01% |
| Jan. 23, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | M | Common Stock | 21316 | $4.30 | 187,306.0000 | 42,900,083 | 12.84% | 0.05% |
| Jan. 23, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | S | Common Stock | 21316 | $12.46 | 165,990.0000 | 42,900,083 | 11.38% | 0.05% |
| Jan. 22, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | M | Stock Option (Right to Buy) | 14559 | $0.00 | 35,313.0000 | 42,900,083 | 29.19% | 0.03% |
| Jan. 23, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | M | Stock Option (Right to Buy) | 21316 | $0.00 | 13,997.0000 | 42,900,083 | 60.36% | 0.05% |
| Jan. 22, 2024 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | S | Common Stock | 14559 | $12.18 | 170,115.0000 | 42,900,083 | 7.88% | 0.03% |
| Feb. 17, 2023 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | A | Stock Option (Right to Buy) | 41000 | $0.00 | 41,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 17, 2023 | Cullinan Therapeutics, Inc. | $CGEM | Savill Corrine | Chief Business Officer | A | Common Stock | 20500 | $0.00 | 170,115.0000 | 0 | 13.70% | 0.00% |